№ files_lp_4_process_2_73849
File format: docx
Character count: 6169
File size: 38 KB
Year:
2021
Region / City:
United Kingdom, Edinburgh
Subject:
Hepatology, Portal Hypertension, Pharmacology
Document Type:
Editorial
Authors:
Naaventhan Palaniyappan, Jonathan A. Fallowfield
Target Audience:
Medical researchers, hepatologists, clinicians
Study Population:
32 cirrhotic patients
Intervention:
Single oral dose of 1g metformin
Comparator:
Placebo
Outcome Measures:
Hepatic venous pressure gradient, hepatic clearance of indocyanine green, hepatic oxygen intake
Funding / Conflicts of Interest:
Research funding from Novartis and Intercept Pharmaceuticals; advisory roles with multiple pharmaceutical companies
Publication:
Alimentary Pharmacology & Therapeutics
Context:
Editorial discussing results from a randomized pilot study examining the immediate impact of metformin on portal pressure in cirrhosis and its potential mechanistic effects on intrahepatic vascular resistance.
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Journal:
World Journal of Gastroenterology
Type of document:
Scientific article
Article type:
Original article; Observational study
Field:
Gastroenterology; Hepatology
Topic:
Cirrhosis; Hepatic encephalopathy; Patient readmission; Mortality risk
Authors:
Xiao-Peng Hu; Jian Gao
Author affiliation:
Second Clinical College, Chongqing Medical University, Chongqing, China; Department of Gastroenterology, Second Affiliated Hospital, Chongqing Medical University, Chongqing, China
Corresponding author:
Jian Gao
Corresponding author position:
Professor; Chief Doctor
Institution:
Second Affiliated Hospital, Chongqing Medical University
City:
Chongqing
Country:
China
Ethics approval:
Ethics Committee of the Second Affiliated Hospital of Chongqing Medical University (No. 2017-064)
Study design:
Observational study
Study period:
January–February 2018
Follow-up period:
6 months
Sample size:
213 patients with cirrhosis
Main variables:
International normalized ratio (INR); Model for End-stage Liver Disease (MELD) score; Hemoglobin level
Primary outcomes:
Early readmission; Mid-term mortality
Received:
April 8, 2019
First decision:
April 30, 2019
Revised:
May 7, 2019
Accepted:
June 8, 2019
Published online:
July 14, 2019
DOI:
10.3748/wjg.v25.i26.3426
License:
Creative Commons Attribution Non Commercial (CC BY-NC 4.0)
Year:
2014
Region / city:
Australia
Topic:
Pharmaceutical product submission
Document type:
Application for listing
Organization / institution:
Pharmaceutical Benefits Advisory Committee (PBAC)
Author:
AstraZeneca Pty Ltd
Target audience:
Health professionals, regulatory authorities
Period of validity:
Not specified
Approval date:
Not specified
Date of changes:
1 April 2014
Year:
2013
Region / City:
UK (Oxford, Luton, Dundee)
Topic:
Clinical Study / Cancer Research
Document Type:
Research Study Summary
Organization / Institution:
Oxford University, University of Southampton
Authors:
Michael Youdell, Andrew Blake, Simon Lord, Costas Savva, Stephen Beers, Francesca Buffa
Target Audience:
Researchers, Medical Professionals
Period of Action:
May 2011 – November 2013
Approval Date:
2013
Date of Modifications:
N/A
Year:
2021
Region / City:
Shanghai, China
Topic:
Inflammatory myofibroblastic tumor, Metformin treatment
Document type:
Case report
Organization / Institution:
Shanghai Children’s Medical Center, Shanghai Jiaotong University School of Medicine
Author(s):
Yu Liang, Hong-Xiang Gao, Rui-Cheng Tian, Jing Wang, Yu-Hua Shan, Lei Zhang, Chen-Jie Xie, Jing-Jing Li, Min Xu, Song Gu
Target audience:
Medical professionals, researchers in oncology and pediatrics
Period of validity:
Not applicable
Approval date:
January 16, 2021
Modification date:
Not applicable
Year:
2018
Region / city:
Australia
Subject:
Pharmaceutical application for diabetes treatment
Document type:
Pharmaceutical submission
Organization / institution:
PBAC, TGA
Author:
Merck Sharp & Dohme (Australia) Pty Ltd
Target audience:
Medical practitioners, healthcare professionals
Validity period:
Ongoing since 2018
Approval date:
16 April 2018
Revision date:
March 2018
Year:
2024
Regulatory authority:
Therapeutic Goods Administration (TGA)
Medicine:
MACITENTAN 10 mg with TADALAFIL 40 mg (Opsynvi®)
Indication:
Pulmonary arterial hypertension (PAH), WHO Group 1, functional class II and III
Therapy type:
Dual or triple combination therapy
Dosage form:
Tablet, fixed dose combination (FDC)
Prescriber type:
Medical practitioners
Restriction type:
Authority Required (Written, Complex Authority Required)
Clinical criteria:
Treatment as dual therapy (MAC+TAD) or triple therapy with prostanoid
Population:
Adult patients with stable PAH on separate doses of macitentan and tadalafil
Previous considerations:
PBAC recommendations for macitentan and tadalafil since 2011–2014
Approval date:
16 September 2024
Source documents:
TGA registration, PBAC meeting minutes, ACM minutes August 2024, FDA, EMA, CDA references
Year:
2021
Region / city:
Australian Capital Territory
Topic:
Hypertension, Pregnancy, Maternity Care
Document Type:
Guideline
Author:
Canberra Health Services
Target Audience:
Medical officers, Registered Midwives, Nurses, Allied Health professionals, Students working under supervision
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2023
Region / City:
Not specified
Topic:
Postpartum hypertension, clinical trials, remote monitoring
Document Type:
Research Article
Organization / Institution:
Not specified
Authors:
Adi Hirshberg, Katheryne Downes, Sindhu Srinivas
Target Audience:
Researchers, healthcare professionals
Period of validity:
Not specified
Approval Date:
Not specified
Date of changes:
Not specified
Year:
2025
Region / City:
Japan
Topic:
Hypertension Research
Document Type:
Form
Institution / Organization:
Japanese Society of Hypertension
Author:
Not specified
Target Audience:
Researchers and medical professionals
Period of Action:
2025
Approval Date:
Not specified
Date of Changes:
Not specified
Note:
Year
Topic:
Clinical trial, Idiopathic Intracranial Hypertension (IIH), vision preservation
Document type:
Participant Information Sheet
Organization / institution:
University of Birmingham
Target audience:
Adults with Idiopathic Intracranial Hypertension (IIH)
Year:
2023
Region / City:
England
Theme:
Healthcare / Clinical Coding
Document Type:
Technical Specification
Organization / Institution:
NHS England
Author:
General Practice Specification and Extraction Service (GPSES), NHS England
Target Audience:
GPES users, GP system suppliers
Effective Period:
2023/2024/2425
Approval Date:
01/04/2023
Amendment Date:
01/04/2024
Note:
Year
Topic:
Endocrine hypertension, primary aldosteronism
Document type:
Position statement
Organization / institution:
European Society of Hypertension, Japan Endocrine Society, Taiwan Society of Aldosteronism
Author:
Paolo Mulatero, Leonardo Sechi, Tracy Ann Williams, Jacques W.M. Lenders, Martin Reincke, Fumitoshi Satoh, Andrzej Januszewicz, Mitsuhide Naruse, Michael Doumas, Franco Veglio, Vin Cent Wu, Jiri Widimsky
Target audience:
Healthcare professionals, researchers in endocrinology and hypertension
Year:
2010-2024
Region / city:
Asia-Pacific
Subject:
Hepatology
Document Type:
Clinical Practice Guidelines
Organization / Institution:
Asian Pacific Association for the Study of the Liver (APASL)
Author:
APASL
Target Audience:
Healthcare professionals
Period of validity:
2010-2024
Date of approval:
2010
Date of revisions:
2024
Context:
Collection of clinical practice guidelines and consensus statements issued by the Asian Pacific Association for the Study of the Liver on various hepatological conditions, including hepatocellular carcinoma, hepatitis B and C, liver transplantation, and metabolic diseases.
Year:
2021
Region / City:
Bangalore, India
Topic:
Medical case report, Dengue in pregnancy
Document type:
Case Report
Institution:
Manipal Hospitals, Bangalore, India
Author:
Dr. Supriya Preman T P, Dr. Nirmal Sheshagiri
Target Audience:
Healthcare professionals, Obstetricians, Intensive care specialists
Period of validity:
N/A
Approval date:
N/A
Date of changes:
N/A
Note:
Contextual description
Year:
2023
Region / city:
Livingstone, Zambia; Lusaka, Zambia; Twickenham, London, UK; Nashville, TN, USA
Subject:
Hypertension, dietary salt, inflammation
Document type:
Research study
Organization / institution:
Mulungushi University, University of Zambia, St. Mary’s University, Vanderbilt University Medical Center
Author:
Sepiso K. Masenga, Leta Pilic, Benson M. Hamooya, Selestine Nzala, Geoffrey Kwenda, Douglas C. Heimburger, Wilbroad Mutale, John R. Koethe, Annet Kirabo, Sody M. Munsaka
Target audience:
Researchers, healthcare professionals
Period of validity:
Not specified
Approval date:
Not specified
Modification date:
Not specified
Year:
2023
Region / city:
United States
Topic:
Hypertension management
Document type:
News report
Organization:
OSF HealthCare
Author:
Not specified
Target audience:
General public
Date of approval:
Not specified
Date of changes:
Not specified
Year:
2026
Region / City:
Baghdad
Topic:
Pharmacology, Hypertension
Document Type:
Educational material
Institution:
College of Dentistry, Baghdad University
Author:
Dr. Zainab Ghalib
Target Audience:
Medical students, healthcare professionals
Period of validity:
Ongoing
Approval Date:
2026-02-23
Date of Changes:
Not specified
Description:
This document provides an overview of hypertension, its classification, pathophysiology, and pharmacological treatments, with a focus on antihypertensive agents and their mechanisms of action.
Year:
2021–2023
Country:
United States
Topic:
Hypertension control and cardiovascular risk
Type of document:
Health news article
Organization:
OSF HealthCare
Author / Speaker:
Jason Trager, DO
Data source:
National Health and Nutrition Examination Survey (NHANES)
Medical field:
Cardiology
Key subjects:
Blood pressure guidelines, lifestyle modification, medication adherence, cardiovascular prevention
Referenced period:
National Heart Month
Geographic focus:
Bloomington, Illinois
Clinical thresholds discussed:
130/80 mm Hg and 140/90 mm Hg
Preventive measures mentioned:
Smoking cessation, DASH diet, exercise, weight loss, sleep apnea treatment, coronary artery calcium scan
Year:
2002
Region / City:
Kathmandu, Nepal
Topic:
Health, Hypertension, Patient Perception, Treatment Adherence
Document Type:
Research Instrument
Organization:
Not specified
Author:
Not specified
Target Audience:
Patients with Hypertension
Period of Validity:
Not specified
Approval Date:
Not specified
Modification Date:
Not specified
Year:
2023
Region / city:
Athens, Greece; Milan, Italy
Topic:
Beta-blockers, hypertension
Document type:
Meta-analysis, Scientific research article
Organization / institution:
Department of Cardiology, Helena Venizelou Hospital, Evangelismos General Hospital of Athens, University Milano-Bicocca, Policlinico di Monza
Author:
Costas Thomopoulos, George Bazoukis, Costas Tsioufis, Giuseppe Mancia
Target audience:
Medical professionals, researchers in cardiology and pharmacology
Period of validity:
N/A
Approval date:
N/A
Modification date:
N/A